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Abstract 
Purpose: Increased systemic cortisol availability during adult critical illness is determined by reduced binding-pro-
teins and suppressed breakdown rather than elevated ACTH. Dynamics, drivers and prognostic value of hypercorti-
solism during pediatric critical illness remain scarcely investigated.
Methods: This preplanned secondary analysis of the PEPaNIC-RCT (N = 1440), after excluding 420 children treated  
with corticosteroids before PICU-admission, documented (a) plasma ACTH, (free)cortisol and cortisol-metabolism at 
PICU-admission, day-3 and last PICU-day, their prognostic value, and impact of withholding early parenteral nutrition 
(PN), (b) the association between corticosteroid-treatment and these hormones, and (c) the association between 
corticosteroid-treatment and outcome.
Results: ACTH was normal upon PICU-admission and low thereafter (p ≤ 0.0004). Total and free cortisol were only 
elevated upon PICU-admission (p ≤ 0.0003) and thereafter became normal despite low binding-proteins (p < 0.0001) 
and persistently suppressed cortisol-metabolism (p ≤ 0.03). Withholding early-PN did not affect this phenotype. On 
PICU-day-3, high free cortisol and low ACTH independently predicted worse outcome (p ≤ 0.003). Also, corticosteroid-
treatment initiated in PICU, which further suppressed ACTH (p < 0.0001), was independently associated with poor 
outcomes (earlier live PICU-discharge: p < 0.0001, 90-day mortality: p = 0.02).
Conclusion: In critically ill children, systemic cortisol availability is elevated only transiently, much lower than in 
adults, and not driven by elevated ACTH. Further ACTH lowering by corticosteroid-treatment indicates active feed-
back inhibition at pituitary level. Beyond PICU-admission-day, low ACTH and high cortisol, and corticosteroid-treat-
ment, predicted poor outcome. This suggests that exogenously  increasing cortisol availability during acute critical 
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Introduction
Increased systemic cortisol availability is essential to 
cope with the severe physical stress imposed by surgery, 
trauma or severe illnesses. It has long been assumed 
that increased systemic cortisol availability in response 
to critical illnesses requiring admission to an intensive 
care unit (ICU) is predominantly driven by a sustained 
activation of the hypothalamus-pituitary-adrenocortical 
(HPA) axis, with a 6–10-fold increase in adrenocortical 
cortisol synthesis and secretion in response to increased 
ACTH release from the anterior pituitary. Also fast-
ing, often a consequence of severe illness, is considered 
a metabolic stressor that can affect the HPA axis [1]. In 
critically ill adults, high as well as low plasma cortisol 
concentrations have been associated with adverse out-
come [2]. More recently, it has become clear that in most 
adult patients, throughout the first 4  weeks in the ICU, 
hypercortisolism is present in the face of low or normal 
rather than high plasma ACTH concentrations, irrespec-
tive of whether or not nutritional goals are targeted early 
[3–5]. Instead of being determined by increased ACTH-
driven cortisol production, the increased systemic corti-
sol availability during critical illness in adults was shown 
to be determined by reduced circulating levels of corti-
sol binding-proteins with suppressed binding affinity and 
by a suppressed cortisol breakdown in liver and kidney, 
which, together, via feedback inhibition, at least partially 
explain the low plasma ACTH [2–4, 6–9].
Although HPA axis alterations have been described in 
children suffering from meningococcal sepsis [10–12], 
the dynamics, drivers and prognostic value of systemic 
cortisol availability in the broader population of criti-
cally ill children have only scarcely been investigated [13, 
14]. Nevertheless, studies have suggested that a substan-
tial proportion of critically ill children may not be able to 
increase systemic cortisol availability enough to face the 
stress of the critical illness, which could cause hemody-
namic instability and systemic hyperinflammation with 
need for vasopressor support [15, 16]. As a consequence, 
pediatric intensivists often prescribe systemic corticos-
teroids, often in quite high doses, although adequately 
powered RCTs investigating its clinical efficacy and safety 
in children are lacking [15, 16]. It currently remains 
debated whether or not such treatment improves mor-
bidity and mortality of critically ill children and some 
studies have suggested possible harm [17–20].
In this study, we aimed at (a) documenting changes 
over time during the course of pediatric critical illness 
in plasma ACTH, (free)cortisol and cortisol metabolites, 
their prognostic value and the impact of withholding 
early supplemental parenteral nutrition (PN), (b) investi-
gating the association between treatment with systemic 
corticosteroids and these parameters, and (c) assessing 
the independent association between treatment with 
systemic corticosteroids and patient-centered clinical 
outcomes.
Materials and methods
Patients and sample collection
This study was a preplanned secondary analysis of the 
multicenter PEPaNIC randomized controlled trial (RCT) 
conducted in Belgium, the Netherlands and Canada 
(June 2012–July 2015) [21]. Written informed consent 
was obtained from parents or legal guardians. The insti-
tutional ethical review board at each participating center 
approved the protocol and consent forms of the study 
(ML8052, NL38772.000.12, Pro00038098), which was 
performed in accordance to the 1964 Declaration of Hel-
sinki and later amendments. The detailed study protocol 
and primary results have been published [21, 22].
The PEPaNIC trial investigated the clinical outcomes of 
withholding supplemental parenteral nutrition (PN) up 
to day 8 in the pediatric ICU (PICU), referred to as “late-
PN”, as compared with early supplemental PN when-
ever enteral nutrition alone was insufficient to reach the 
caloric target, referred to as “early-PN”. Children aged 
0–17  years were eligible for inclusion, if a PICU-stay 
of 24  h or more was expected, if they had a moderate 
or severe risk of malnutrition (score ≥ 2 on the Screen-
ing Tool for Risk on Nutritional Status and Growth 
(STRONGkids)), and if none of the predefined exclusion 
criteria were met.
illness in children may be inappropriate. Future studies on corticosteroid-treatment in critically ill children should plan 
safety analyses, as harm may be possible.
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Take‑home message 
Despite low plasma cortisol binding proteins and reduced cortisol 
metabolism, systemic cortisol availability in critically ill children is 
elevated only transiently and to a much lower extent than in adults, 
and is not driven by elevated ACTH. Beyond the day of PICU-
admission, low ACTH and high cortisol, as well as corticosteroid-
treatment, independently predicted poor outcome, suggesting that 
exogenously increasing systemic cortisol availability during acute 
illness in children may be inappropriate.
Enteral nutrition was started as soon as possible in 
both groups. In the early-PN group, supplemental PN 
was initiated within 24 h after PICU-admission to reach 
the caloric target (Online Resource Table_1-2), whereas 
PN was withheld up to the morning of PICU day 8 for 
patients in the late-PN group. Although labeled “late-PN” 
group, the majority of these patients needed intensive 
care for less than 8 days and thus did not receive PN. In 
the late-PN group, a mixture of intravenous dextrose (5%) 
and saline was administered to match the intravenous 
fluid load given to the early-PN patients. Patients in both 
groups equally received intravenous trace elements, min-
erals and vitamins, and blood glucose control with insu-
lin according to local targets. Blood was sampled upon 
admission and then daily at 6 a.m. until PICU-discharge 
or death, within limitations for amount of blood sampling 
allowed by the institutional ethical review boards per 
center. For the quantification of hormonal parameters of 
the HPA axis, blood samples were collected in pre-chilled 
EDTA tubes and immediately placed on ice, centrifuged 
at 4  °C, with plasma stored at − 80  °C until assay. Daily 
urine samples from a 24-h urine collection were stored in 
Vacuette urine tubes at − 80 °C until quantification of the 
cortisol metabolites.
To investigate the time course of the changes in plasma 
concentrations of ACTH, total cortisol, free cortisol, CBG 
and albumin during critical illness in children (Fig.  1, 
Panel_A.1), patients who received corticosteroids within 
3  days before inclusion (including in the emergency 
room) or prior to the blood sampling day were excluded, 
as well as those patients who died in PICU on the day of 
blood sampling to avoid bias evoked by the agonal stress 
442 pts 
with plasma ACTH, total cortisol, CBG, albumin and free cortisol concentrations
available upon PICU admission and day 3 or last PICU day for shorter stay
A. Changes in the HPA axis during the course of critical illness in children
A.3. Effect of accepting early macronutrient deficits on the HPA axis changes
Early-PN
207 pts
Late-PN
207 pts
propensity score
matched
A.4. Predictive value of plasma ACTH and free cortisol for clinical outcome
Upon
PICU admission
442 pts
On PICU day 3
230 long-stay pts
Clinical
outcomes
PICU admission
442 pts
D3 (230 long-stay pts)
or 
LD (212 short-stay pts)
LD beyond D3 
140 long-stay pts
64 healthy
controls
A.1. Plasma profiles of ACTH, total cortisol, CBG, albumin and free cortisol
PICU admission
76 pts
D3 (52 long-stay pts)
or 
LD (24 short-stay pts)
LD beyond D3 
32 long-stay pts
25 healthy
controls
A.2. Estimation of cortisol metabolism via urinary cortisol metabolites
1440 pts in PEPaNIC RCT
pts who received CS
within 3 days prior to PICU admission (N=420)
pts who received CS in PICU
prior to blood sampling day (N=466)
pts who died on the 
blood sampling day (N=26)
no or insufficient PICU admission or day3/LD
plasma sample for HPA axis measurements (N=86)
C. Association of CS administration in PICU
with clinical outcome, adjusted for risk factors
B. Impact of CS administration in PICU on HPA axis changes
No CS in PICU
750 pts
CS in PICU
270 pts
First day of CS
33 pts
Equivalent day no CS
33 pts
1020 pts who did not receive CS within 3 days prior to PICU admission
33 pts who received CS in PICU with plasma 
ACTH, total cortisol, CBG, albumin and free cortisol
concentrations available on morning after first CS administration
1:1 matched
with pts who 
did not receive
CS in PICU
No CS in PICU
435 pts
CS in PICU
217 pts
All pts
Long-stay pts
Fig. 1 Diagram of the study design. ACTH adrenocorticotropic hormone, CBG cortisol-binding globulin, CS corticosteroids, D3 day 3 in PICU, HPA 
axis hypothalamus–pituitary–adrenal axis, LD last day in PICU, PEPaNIC early versus late parenteral nutrition in the pediatric intensive care unit, PICU 
pediatric intensive care unit, PN parenteral nutrition, RCT randomized controlled trial. Short-stay patients are patients who needed intensive care for 
1 or 2 days, long-stay patients are patients who needed intensive care for at least 3 days
response. Of the remaining patients, we included those 
442 patients for whom plasma samples were available 
upon admission and on day 3 (for 230 long-stay patients 
treated in PICU for at least 3 days, which is the median 
duration of PICU stay, Table 1) or last PICU day (for 212 
short-stay patients treated in PICU for < 3 days). For com-
parison, 64 healthy children, who had never been criti-
cally ill and from whom blood was drawn immediately 
after intravenous catheterization prior to minor elec-
tive surgery, age- and gender-matched with the patients, 
were included (Fig.  1, Panel_A.1). The prognostic value 
for the clinical outcomes (new infection acquired in the 
PICU, time to live discharge from PICU and 90-day mor-
tality) of the admission plasma concentrations of ACTH 
and free cortisol was assessed among these 442 patients 
(Fig.  1, Panel_A.4). The prognostic value of plasma 
ACTH and free cortisol on day 3 was also assessed for the 
230 long-stay patients (Fig. 1, Panel_A.4). For the estima-
tion of the activity of cortisol-metabolizing enzymes via 
urinary cortisol metabolites, a representative subset of 76 
patients and 25 age- and gender-matched healthy control 
children was selected (Fig. 1, Panel_A.2).
To investigate whether late-PN, as compared with 
early-PN, altered the changes in endogenous, illness-
induced HPA axis parameters, between PICU admission 
and day 3 or last PICU day for patients discharged earlier 
(Fig.  1, Panel_A.3), a propensity score-matched patient 
subset was selected, given the required exclusion of a 
substantial number of patients. Propensity scores were 
estimated with logistic regression based on baseline risk 
factors as covariates, including treatment center, risk of 
malnutrition (STRONGkids score), age group, diagnosis 
upon admission, severity of illness (PeLOD score reflect-
ing degree of organ failure and PIM2 score estimating 
risk of death) and sepsis upon admission [23–26]. One-
to-one nearest neighbor-matching without replacement 
and a caliper of 0.3 retained 414 patients.
To investigate the association between treatment with 
corticosteroids in the PICU and plasma concentrations 
of ACTH, total cortisol, free cortisol, CBG and albumin 
(Fig. 1, Panel_2), the 33 patients who had a measurement 
the morning after the first day of corticosteroid-treat-
ment were matched case-by-case to patients who had not 
been treated with corticosteroids and for whom a meas-
urement was available for the same PICU-stay day (Fig. 1, 
Panel_2, Online Resource Methods_1). Distinction was 
made between hydrocortisone and synthetic corticos-
teroids given that the latter are not detected by the assay 
used for quantifying cortisol.
To investigate the independent association between 
treatment with corticosteroids initiated in the PICU 
and patient-centered clinical outcomes (new infection 
acquired in the PICU, time to live discharge from PICU 
and 90-day mortality) (Fig. 1, Panel_4), all 1020 patients 
who had not been treated with corticosteroids before 
PICU admission were included.
Plasma and urinary analyses
Plasma ACTH concentrations were quantified by dou-
ble-monoclonal immunoradiometric assay (Brahms 
Diagnostics) and plasma cortisol (Immunotech) and 
cortisol-binding-globulin (CBG) (Riazen) by competi-
tive radioimmunoassay. Plasma albumin was quantified 
by the bromocresol-green colorimetric method (Sigma-
Aldrich). Plasma free cortisol was calculated with the 
Coolens formula adapted for individual albumin and 
CBG concentrations, which has previously been validated 
as representative for measured plasma free cortisol con-
centrations in the ICU context [6, 27]. After deglucoroni-
dation, the absolute urinary concentrations of cortisol (F), 
5α-tetrahydrocortisol (allo-THF), 5β-tetrahydrocortisol 
(THF), cortisone (E), 5α-tetrahydrocortisone (allo-THE) 
and tetrahydrocortisone (THE) were determined with 
liquid chromatography-tandem mass spectrometry (LC–
MS/MS) as reported previously [4].
Statistical analyses
For research question A and C (Fig. 1), sample size was 
determined by availability. For research question B 
(Fig. 1), given lack of data for children in the PICU, sam-
ple size was determined based on published data regard-
ing the impact of exogenous corticosteroids on plasma 
ACTH outside the context of critical illness [28, 29]. To 
detect a lowering in plasma ACTH in this order of mag-
nitude, with 80% power and 95% certainty, 33 patients 
per group were required.
Continuous data and proportions were compared with 
Wilcoxon Rank Sum and Chi square tests, respectively. 
Data are presented as medians and interquartile ranges 
or numbers and percentages.
Independent associations of plasma concentrations of 
ACTH and free cortisol, or of corticosteroid-treatment, 
with patient-centered clinical outcomes were analyzed 
with multivariable logistic regression and proportional 
hazard analyses, adjusted for baseline risk factors [treat-
ment center, risk of malnutrition (STRONGkids score), 
age group, diagnosis upon admission, severity of illness 
(PeLOD and PIM2), sepsis upon admission] [23–26]. 
Effect sizes are reported as odds ratios (OR) and hazard 
ratios (HR), respectively, with 95% confidence intervals 
(CI).
Propensity score matching was performed with SPSS 
R-menu R3.1 (Foundation for Statistical Computing) in 
IBM SPSS Statistics 25.0.0.0 (SPSS, Chicago, IL). All anal-
yses were performed with  JMP®Pro14.0.0 (SAS Institute 
Table 1 Characteristics of PICU patients and healthy control children
HPA axis changes Association of CS administration with HPA axis Association of CS 
administration 
with outcomePatients Controls P No CS CS P
Baseline characteristics N = 442 N = 64 N = 33 N = 33 N = 1020e
Age (years), median (IQR) 2.6 (0.4–7.6) 2.0 (0.7–6.7) 0.68 6.4 (1.1–11.5) 3.1 (0.8–10.8) 0.37 1.4 (0.3–6.7)
Age < 1 year, N (%) 167 (37.8) 25 (39.1) 0.84 8 (24.2) 10 (30.3) 0.58 463 (45.4)
Male gender, N (%) 250 (56.5) 37 (57.8) 0.85 21 (63.6) 21 (63.6) > 0.99 593 (58.1)
Weight (SD score), median 
(IQR)
− 0.5 (− 1.4 to 0.5) 0.1 (− 0.6 to 0.8) − 0.4 (− 1.4 to 0.6) 0.12 − 0.5 (− 1.4 to 0.5)
Height (SD score), median 
(IQR)
− 0.4 (− 1.5 to 0.6) − 0.2 (− 1.2 to 1.2) − 0.2 (− 1.3 to 0.9) 0.63 − 0.4 (− 1.5 to 0.7)
Treatment center, N (%) 0.55
 Leuven 387 (87.6) 23 (69.7) 19 (57.6) 544 (53.3)
 Rotterdam 46 (10.4) 8 (24.2) 12 (36.4) 401 (39.3)
 Edmonton 9 (2) 2 (6.1) 2 (6.1) 75 (7.4)
STRONGkids risk level, N (%)a 0.55
 Medium 415 (93.9) 32 (97) 31 (93.9) 907 (88.9)
 High 27 (6.1) 1 (3.0) 2 (6.1) 113 (11.1)
PeLOD score, first 24 h in 
PICU, median (IQR)b
23 (21–32) 21 (12–32) 23 (10–32) 0.60 21 (11–31)
PIM2 score, median (IQR)c − 2.9 (− 3.8 to − 1.8) − 2.9 (− 4.1 to − 1.3) − 3.0 (− 3.8 to − 1.7) 0.89 − 2.8 (− 3.7 to − 1.6)
PIM2 probability of death, %, 
median (IQR)
5.2 (2.3–14.5) 4.6 (2.2–13.9) 5.4 (2.3–15.3) 0.97 5.8 (2.3–17)
Emergency admission, N (%)d 168 (38) 17 (51.5) 16 (48.5) 0.80 615 (60.3)
Diagnostic group, N (%) 0.92
 Surgical
  Abdominal 16 (3.6) 0 (0) 0 (0) 112 (11)
  Burns 3 (0.7) 0 (0) 0 (0) 10 (1)
  Cardiac 222 (50.2) 10 (30.3) 10 (30.3) 294 (28.8)
  Neurosurgery-traumatic 
brain injury
35 (7.9) 8 (24.2) 8 (24.2) 80 (7.8)
  Thoracic 21 (4.8) 1 (3) 2 (6.1) 57 (5.6)
  Transplantation 0 (0) 0 (0) 1 (3) 8 (0.8)
  Orthopedic surgery-
trauma
41 (9.3) 3 (9.1) 2 (6.1) 53 (5.2)
  Other 11 (2.5) 2 (6.1) 1 (3) 39 (3.8)
 Medical
  Cardiac 18 (4.1) 2 (6.1) 2 (6.1) 59 (5.8)
  Gastrointestinal-Hepatic 2 (0.5) 0 (0) 0 (0) 4 (0.4)
  Oncologic-Hematologic 0 (0) 0 (0) 1 (3) 9 (0.9)
  Neurologic 22 (5) 1 (3) 1 (3) 84 (8.2)
  Renal 0 (0) 0 (0) 0 (0) 1 (0.1)
  Respiratory 28 (6.3) 0 (0) 0 (0) 141 (13.8)
  Other 23 (5.2) 6 (18.2) 5 (15.2) 69 (6.8)
Condition on admission, N (%)
 Mechanical ventilation 
required
391 (88.5) 28 (84.9) 28 (84.9) > 0.99 875 (85.8)
 ECMO or other assist device 
required
7 (1.6) 0 (0) 1 (3) 0.23 29 (2.8)
 Infection 123 (27.8) 12 (36.4) 11 (33.3) 0.79 429 (42.1)
 Sepsis 93 (21) 11 (33.3) 9 (27.3) 0.59 308 (30.2)
Randomization group, N (%) 0.20
 Early PN 227 (51.4) 15 (45.5) 10 (30.3) 504 (49.4)
Inc, Cary, NC). Two-sided p values < 0.05 were consid-
ered to indicate statistical significance.
Results
For the three main research questions, depicted in Fig. 1, 
comparisons of the patient characteristics are provided in 
Table 1 and Online Resource Table_3-4.
Time course of the changes in plasma concentrations 
of ACTH, total cortisol, free cortisol, CBG, and albumin 
and estimations of cortisol metabolism during critical 
illness, prognostic value and impact of late‑PN 
versus early‑PN
Upon PICU-admission, plasma ACTH concentrations 
were not significantly different from those in the matched 
healthy children and became low thereafter throughout 
PICU stay (Fig. 2a). Plasma total cortisol concentrations 
were only above normal at PICU-admission and became 
normal thereafter (Fig.  2b). Also, plasma free cortisol 
concentrations were only higher than in healthy children 
upon PICU-admission. Thereafter, plasma free cortisol 
levels were no longer elevated (Fig.  2c), despite plasma 
CBG and albumin concentrations that were mostly low 
(Fig.  2d, e) and despite the observation that the esti-
mated activities of cortisol-metabolizing enzymes, 
11β-hydroxysteroid-dehydrogenase-2 and the A-ring 
reductases 5α-reductase and 5β-reductase, remained low 
throughout PICU stay (Fig. 2f–i).
The use of late-PN, as compared with early-PN, did not 
affect the changes over time in plasma concentrations of 
ACTH, (free)cortisol, CBG, or albumin (Online Resource 
Fig. 1).
Adjusted for baseline risk factors, including type and 
severity of illness among others, upon PICU-admission 
plasma concentrations of ACTH and free cortisol were 
not independently associated with the clinical outcomes 
(Online Resource Table_5). However, among long-stay 
patients, higher plasma ACTH concentrations on day 3 
in the PICU were independently indicative of a higher 
likelihood of earlier live discharge from PICU, whereas 
higher plasma free cortisol concentrations on that day 
were independently indicative of a lower likelihood of 
earlier live discharge from PICU (Table 2). There were no 
independent associations between plasma ACTH or free 
cortisol on day 3 and the risk of new infections or the risk 
of 90-day mortality.
Association between treatment with corticosteroids 
initiated in the PICU and plasma concentrations of ACTH, 
total cortisol, free cortisol, CBG and albumin
Among the 33 selected patients who received corticos-
teroids on median day 2 (IQR 1-3), 28 received synthetic 
corticosteroids and 5 received hydrocortisone. Corti-
costeroid-treatment further suppressed plasma con-
centrations of ACTH as compared with the 33 matched 
patients who did not receive corticosteroids and were 
also assessed on median day 2 (IQR 1-3) (Fig. 3). Expect-
edly, the use of synthetic corticosteroids lowered plasma 
total and free cortisol concentrations (Fig.  3), whereas 
hydrocortisone increased plasma total and free cortisol. 
There was no association with the plasma concentrations 
of CBG or albumin.
Independent association between treatment 
with corticosteroids initiated in the PICU 
and patient‑centered clinical outcomes
Of the 1020 patients who had not been treated with corti-
costeroids prior to PICU admission, 270 (26.5%) received 
corticosteroids initiated on median day 2 (IQR 1–5) after 
admission to the PICU. Among the 652 long-stay patients 
in PICU for at least 3 days, 217 (33.3%) received corticos-
teroids initiated on median day 3 (IQR 1–6) after PICU 
Table 1 (continued)
HPA axis changes Association of CS administration with HPA axis Association of CS 
administration 
with outcomePatients Controls P No CS CS P
 Late PN 215 (48.6) 18 (54.6) 23 (69.7) 516 (50.6)
Duration of PICU stay, days, 
median (IQR)
3 (1–6) 2 (1–3) 2 (1–3) > 0.99 4 (2–8)
Acquisition of a new infec-
tion in PICU, N (%)
47 (10.6) 1 (3) 2 (6.1) 0.55 140 (13.7)
90-day mortality, N (%) 12 (2.7) 2 (6.1) 4 (12.1) 0.39 61 (6)
a Evaluates risk of malnutrition with scores ranging from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and 
a score of 4–5 indicating high risk. bScores range from 0 to 71, with higher scores indicating more severe illness. cHigher scores indicate a higher risk of mortality. 
dElective admissions comprise those requiring post-operative intensive care after scheduled surgery (often complex cardiac surgery or surgery on other vital 
organ systems). Unplanned transfers to the PICU from the general pediatric ward, from the emergency department or from elsewhere are considered emergency 
admissions. eOf whom 270 received CS. CS corticosteroids, ECMO extracorporeal membrane oxygenation, HPA axis hypothalamic–pituitary–adrenal axis. PeLOD 
pediatric logistic organ dysfunction score first 24 h in PICU. PICU pediatric intensive care unit. PIM2 pediatric index of mortality 2 score. PN parenteral nutrition, 
STRONGkids screening tool for risk on nutritional status and growth
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Fig. 2 Time course of the changes in plasma concentrations of ACTH, total cortisol, free cortisol, CBG and albumin, and estimations of cortisol 
metabolism during critical illness. Plasma concentrations of ACTH (a), total cortisol (b), free cortisol (c), CBG (d) and albumin (e) were quantified, 
and activities of the cortisol metabolizing enzymes 11β-HSD2 (f), 5α-reductase (g) and 5β-reductase (h, i) were estimated upon PICU admission, on 
PICU day 3 or last PICU day for patients with a shorter PICU stay, and on the last PICU day beyond day 3 if still in PICU beyond day 3. Results overall 
apply irrespective of the presence of sepsis, and irrespective of whether patients were admitted after cardiac surgery or for other reasons. Box 
plots show medians, interquartile ranges, and 10th and 90th percentiles. The grey bars represent the interquartile ranges obtained for the healthy 
control children, with the white lines indicating the medians. ACTH: adrenocorticotropic hormone, aTHF: allo-THF (5α-tetrahydrocortisol), 11β-HSD2: 
11β-hydroxysteroid-dehydrogenase type 2, CBG: cortisol-binding globulin, D3: day 3 in PICU, E: cortisone, F: cortisol, LD short-stay: last day in PICU 
for patients who needed intensive care for 1 or 2 days, LD long-stay: last day in PICU beyond day 3 for long-stay patients who needed intensive care 
for at least 3 days, PICU: pediatric intensive care unit, THE: tetrahydrocortisone, THF: 5β-tetrahydrocortisol
Table 2 Prognostic value of the changes in the HPA axis for patient‑centered clinical outcomes and independent associa‑
tion between treatment with corticosteroids in the PICU and those outcomes
a Long-stay patients are patients who needed intensive care for at least 3 days. Patients who received corticosteroids within the three days prior to PICU admission 
were excluded from these analyses. bFor the model on the association of CS administration in PICU with new infections, only infections occurring beyond the first 
day of CS administration were considered (“left-truncation”). cInfants are patients younger than 1 year. dEvaluated with the Screening Tool for Risk on Nutritional 
Status and Growth (STRONGkids) with scores ranging from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a 
score of 4–5 indicating high risk. eScores range from 0 to 71, with higher scores indicating more severe illness. fHigher scores indicate a higher risk of mortality. ACTH: 
adrenocorticotropic hormone, CI confidence interval, CS corticosteroids, HPA axis hypothalamus–pituitary–adrenal axis, HR hazard ratio, OR odds ratio, PeLOD pediatric 
logistic organ dysfunction score first 24 h in PICU, PICU pediatric intensive care unit, PIM2 pediatric index of mortality 2 score, PN parenteral nutrition
Prognostic value of HPA axis changes in long‑
stay  patientsa N = 230
Association of CS administration 
in PICU with outcome of long‑stay 
 patientsa N = 652
OR/HR (95%CI) P OR/HR (95%CI) P
Risk of new  infectionb
 Infant versus  childc 1.082 (0.427–2.743) 0.86 1.143 (0.680–1.922) 0.61
 Center—Rotterdam versus Leuven 3.567 (1.014–12.547) 0.04 1.563 (0.796–3.072) 0.19
 Center—Edmonton versus Leuven 0.000 (0.000–inf ) 0.99 2.192 (0.944–5.089) 0.06
 High versus medium risk of  malnutritiond 2.241 (0.601–8.357) 0.22 1.934 (1.053–3.554) 0.03
 PeLOD score (per unit added)e 1.046 (0.991–1.103) 0.09 1.033 (1.006–1.060) 0.01
 PIM2 score (per unit added)f 1.518 (1.080–2.135) 0.01 1.306 (1.095–1.558) 0.003
 Diagnostic group 0.004 0.94
 Sepsis versus no sepsis upon admission 0.218 (0.068–0.700) 0.01 0.411 (0.236–0.714) 0.001
 Randomization to late-PN versus early-PN 0.540 (0.242–1.202) 0.13 0.507 (0.320–0.802) 0.003
 ACTH (per pg/ml added) 0.987 (0.967–1.007) 0.15
 Free cortisol (per µg/ml added) 1.082 (0.861–1.359) 0.52
 CS therapy versus no CS therapy in PICU 1.057 (0.648–1.724) 0.82
Likelihood of earlier live PICU discharge
 Infant versus  childc 0.709 (0.513–0.983) 0.03 0.788 (0.652–0.953) 0.01
 Center—Rotterdam versus Leuven 0.830 (0.516–1.311) 0.42 0.752 (0.594–0.954) 0.01
 Center—Edmonton versus Leuven 1.191 (0.406–2.789) 0.72 0.928 (0.672–1.264) 0.63
 High versus medium risk of  malnutritiond 1.076 (0.561–1.894) 0.81 0.832 (0.641–1.066) 0.14
 PeLOD score (per unit added)e 0.998 (0.980–1.017) 0.85 0.990 (0.981–1.000) 0.04
 PIM2 score (per unit added)f 0.719 (0.633–0.813) < 0.0001 0.785 (0.732–0.842) < 0.0001
 Diagnostic group 0.11 0.15
 Sepsis versus no sepsis upon admission 1.038 (0.715–1.508) 0.84 0.925 (0.765–1.118) 0.42
 Randomization to late-PN versus early-PN 1.006 (0.758–1.337) 0.96 1.336 (1.132–1.578) 0.0006
 ACTH (per pg/ml added) 1.009 (1.003–1.013) 0.0003
 Free cortisol (per µg/ml added) 0.906 (0.840–0.964) 0.003
 CS therapy versus no CS therapy in PICU 0.677 (0.563–0.814) < 0.0001
Risk of 90-day mortality
 Infant versus  childc 1.871 (0.290–12.058) 0.51 1.602 (0.727–3.529) 0.24
 Center—Rotterdam versus Leuven 0.134 (0.007–2.478) 0.17 1.139 (0.442–2.939) 0.78
 Center—Edmonton versus Leuven 0.000 (0.000–inf ) 0.99 0.000 (0.000–inf ) 0.99
 High versus medium risk of  malnutritiond 2.387 (0.223–25.502) 0.47 0.693 (0.220–2.185) 0.53
 PeLOD score (per unit added)e 0.943 (0.845–1.052) 0.27 1.011 (0.973–1.051) 0.57
 PIM2 score (per unit added)f 2.722 (1.435–5.165) 0.0004 1.860 (1.435–2.411) < 0.0001
 Diagnostic group 0.61 0.79
 Sepsis versus no sepsis upon admission 0.966 (0.141–6.613) 0.97 1.322 (0.571–3.058) 0.51
 Randomization to late-PN versus early-PN 0.285 (0.051–1.586) 0.15 0.498 (0.235–1.057) 0.06
 ACTH (per pg/ml added) 0.979 (0.937–1.023) 0.30
 Free cortisol (per µg/ml added) 1.190 (0.775–1.827) 0.48
 CS therapy versus no CS therapy in PICU 2.307 (1.125–4.731) 0.02
admission. Adjusted for baseline risk factors, the use of 
corticosteroids during PICU stay was independently 
associated with a lower likelihood of an earlier live dis-
charge from ICU and with a higher risk of 90-day mor-
tality for all patients (Online Resource Table_6) and for 
long-stay patients alike (Table  2). There was no inde-
pendent association between use of corticosteroids and 
the risk of new infections.
Discussion
In this study of critically ill children admitted to the 
PICU, plasma ACTH concentrations were either normal 
or low and were further lowered by the use of exogenous 
corticosteroids. Total and free plasma cortisol levels were 
elevated only briefly, thereafter lowering to normal lev-
els despite persistently low circulating levels of cortisol 
binding-proteins and despite suppressed cortisol metab-
olism throughout PICU stay. Withholding supplemental 
PN during the first week in PICU did not affect this phe-
notype. Adjusted for risk factors, upon admission plasma 
concentrations of ACTH or free cortisol did not hold 
prognostic value for patient-centered clinical outcomes 
whereas on day 3 in the PICU, a high free cortisol and a 
low plasma ACTH level independently predicted worse 
outcome. Also, treatment with systemic corticosteroids 
initiated during the first few days in the PICU, which 
further suppressed ACTH, was found to independently 
associate with poor outcomes, adjusted for other risk 
factors.
Systemic cortisol availability in critically ill children 
treated in the PICU was found to be elevated only tran-
siently and to a much lesser extent than was previously 
reported for adults [3, 5, 30]. The finding that plasma 
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Fig. 3 Association between treatment with corticosteroids initiated 
in the PICU and plasma concentrations of ACTH, total cortisol, free 
cortisol, CBG, and albumin. Plasma concentrations of ACTH (a), total 
cortisol (b), free cortisol (c), CBG (d) and albumin (e) were quanti-
fied on the morning after the first day of CS administration and on 
equivalent days for patients who did not receive corticosteroids, 
manually matched 1:1 with the patients who received CS. To evaluate 
the association between CS administration and total and free cortisol, 
a distinction was made between hydrocortisone and synthetic CS, 
since the radioimmunoassay for cortisol does not measure synthetic 
CS. Box plots show medians, interquartile ranges, and 10th and 90th 
percentiles. The grey bars represent the interquartile range obtained 
for the healthy control children, with the white lines indicating the 
medians. P values represent the comparison of CS (or type of CS) ver-
sus no CS administration. ACTH: adrenocorticotropic hormone, CBG: 
cortisol-binding globulin, CS: corticosteroids, PICU: pediatric intensive 
care unit, PN: parenteral nutrition
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ACTH in patients was never significantly higher than 
in matched healthy children, not even in the presence 
of elevated plasma cortisol upon PICU-admission, was 
in line with previous adult data [3, 5, 30]. These find-
ings suggest that peripheral mechanisms, such as low 
plasma binding and suppressed cortisol breakdown, are 
active to increase and maintain cortisol availability also 
in the pediatric critically ill population [3, 9]. The obser-
vation that exogenous corticosteroids further suppressed 
plasma ACTH suggests that ACTH is not fully endog-
enously suppressed during pediatric critical illness and 
thus that central activators balance against suppressors 
in exogenous corticosteroid-naive patients but that pitui-
tary feedback inhibition remains responsive to a further 
increase of glucocorticoid signaling.
The low plasma ACTH observed beyond the PICU-
admission day in the critically ill children cannot be 
brought about by feedback-inhibition through free cor-
tisol, given that free cortisol was no longer elevated, 
unless the set-point for feedback inhibition would be 
lower in this context. A lower set-point for feedback 
inhibition by thyroid hormones has also been suggested 
as an explanation for the low T3 syndrome of critical 
illness [31–33]. Absence of elevated free cortisol con-
centrations after a few days in the PICU, while corti-
sol binding-proteins were low and cortisol metabolism 
was suppressed, suggests that the concomitantly low 
ACTH must have played a role. Endogenous or iatro-
genic suppressors of ACTH may be involved. Candidate 
endogenous suppressors of ACTH are elevated levels 
of bile acids as these have shown to be able to cross 
the blood–brain barrier and act as ligands for the glu-
cocorticoid receptor, hereby potentially suppressing 
corticotropin-releasing hormone and hereby suppress-
ing ACTH [34–36]. The use of opioids and other drugs 
in the PICU may have added suppressive effects on the 
HPA axis [30, 37, 38].
Admission levels of plasma ACTH and cortisol did not 
hold prognostic value for clinical outcome when adjusted 
for type and severity of illness and other risk factors. 
Hence, they appeared to be merely a correlate of the type 
and severity of illness. However, it was striking to observe 
that among long-stay patients, after extensive adjustment 
for risk factors including type and severity of illness, a 
high plasma free cortisol and a low plasma ACTH on day 
3, a time point where both cortisol and ACTH levels were 
lowered as compared with PICU admission, together 
were independently predictive of poor outcome. Also, 
exogenous steroid treatment initiated during the first few 
days in the PICU, which further lowered plasma ACTH, 
was predictive of poor outcome after extensive adjust-
ment for risk factors. Together these findings may sug-
gest that the amount of cortisol availability required for 
an effective struggle for survival and recovery from criti-
cal illness in children may not be as high as previously 
assumed and lower than in adults. Excessive amounts 
of cortisol could indeed also be harmful [18, 19]. Alter-
natively, a direct role of endogenous and/or exogenous 
ACTH suppressors in mediating the independent asso-
ciation between low plasma ACTH and adverse outcome 
is possible and cannot be excluded from this study.
The strengths of this study are the large sample size 
of a heterogeneous cohort of critically ill children and 
the use of samples and data from a well-documented 
RCT which allowed to carefully adjust for prospectively 
registered confounders and which allowed case-by-case 
matching. A weakness of the study is that data were 
predominantly gathered during the first week in the 
PICU so that no conclusions can be drawn on a more 
prolonged phase of pediatric critical illness. Another 
weakness is the observational nature of our analy-
ses of the associations with patient-centered clinical 
outcomes, which (although adjusted for baseline risk 
factors) cannot fully take into account potential con-
founding factors such as disease course. Lastly, free 
cortisol concentrations were not directly measured but 
calculated.
In conclusion, cortisol availability during pediatric 
critical illness is only briefly elevated, driven by periph-
eral rather than central mechanisms, and is followed by 
low ACTH and normal free cortisol levels until PICU-
discharge. Low ACTH is further lowered by treatment 
with corticosteroids suggesting active feedback inhibition 
at the pituitary level. Beyond PICU-admission day, a high 
circulating cortisol as well as the administration of sys-
temic corticosteroids appeared independent predictors of 
adverse outcome. These findings raise the hypothesis that 
increasing cortisol availability during the first days after 
onset of critical illness in children may be inappropriate. 
Studies investigating the effect of treatment with corti-
costeroids in critically ill children should thus carefully 
plan interim safety analyses to avoid possible harm.
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